Resources

Type of publications
Regions
Diseases

5192 results found

2025 ∙ Rai, S. Tripathi, S.

Comparative efficacy of leading COVID-19 vaccines: A netwometa-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Ma, K. Christensen, M. Turnbull, M.

Comparative synthesis of sociocultural and political influences (SPIs) on COVID-19 vaccine hesitancy: an interdisciplinary systematic review

  • Adults
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Santos, S. A. D. Sato, M. Y. Basilio, P. H. G. Pereira, M. E. Juliao, R. C. Arruda, N. D. C. Silva, D. P. D. Oliveira, C. S. Costa-Junior, V. H. D. S. Guiloski, I. C.

Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials

  • Adolescents
  • Adults
  • Human papillomavirus (HPV)
  • Safety
Methodological quality (AMSTAR 2):
Low
2025 ∙ Goldsmith, J. J. Tavlian, S. Vu, C. Regan, A. K. Campbell, P. T. Sullivan, S. G.

Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis

  • Newborn
  • Children
  • Influenza
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Moderate
2025 ∙ Abo Zeid, M. Elrosasy, A. Farho, M. A. Rifai, M. Aboelkhier, M. M. Elkhrashy, M. N. Zabady, A. H. Zaki, M. S. A. Hamed, E. M. Dawood, S. A. Abuzaid, Y.

Comparison of safety and immunogenicity between Healive, Havrix and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis

  • All age groups
  • Hepatitis A
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Fletcher, M. A. Okasha, O. Baay, M. Syrochkina, M. Hayford, K.

Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022

  • All age groups
  • Pneumococcal disease
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Wang, Z. Zhang, H. Zhu, Y. Jiang, Y. Yang, D. Zou, X. Fang, Y.

Comprehensive evaluation of prophylactic HPV vaccines: a systematic review and meta-analysis of efficacy, safety, and immunogenicity in males and females

  • All age groups
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Wang, W. Sawleshwarkar, S. Piraveenan, M.

Computational approaches of modelling human papillomavirus transmission and prevention strategies: a systematic review

  • All age groups
  • Human papillomavirus (HPV)
  • Modeling
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Samal, J. Preetha, G. S. Kumar, R. P. Lakshman, N. Dehury, R. K. Singh, H.

Coronavirus Disease 2019 Vaccine Hesitancy and Acceptance among the Indian Population: A Systematic Review and Meta-Analysis

  • South-East Asia
  • India
  • Adolescents
  • Adults
  • Older adults
  • Healthcare workers
  • Parents/caregivers
  • Pregnant women
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Felsher, M. Fisher-Borne, M. Malik, T. Santpurkar, N. Martin, S. Zaidi, O. Wang, W. Palmer, C.

Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review

  • Children
  • Adolescents
  • Adults
  • Older adults
  • Human papillomavirus (HPV)
  • Economic aspects
  • Modeling
Methodological quality (AMSTAR 2):
Not applicable
Loading...